drugset / Trial / NCT05010707

Transgender Estradiol Affirming Therapy

NCT05010707

Phase 2 Completed 39 enrolled Washington University School of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.

Timeline

Start
2021-08-02
Primary completion
2023-08-01
Completion
2024-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator 17-beta estradiol Unknown 100 ug Other
Comparator 17-beta estradiol Unknown 1 mg Other
Comparator 17-beta estradiol Unknown 2 mg Other
Comparator Spironolactone Small molecule 50 mg

Indications

No indication recorded.